19 results about "Bifidobacterium breve" patented technology

The application discloses a preparation method and application of a composite strain of a sugar-controlling probiotic, and belongs to the technical field of microorganisms. The method comprises the steps of strain stock solution preparation, anaerobic culture, pH value determination and regulation, and composite strain proportioning. Through a dynamic shunting mechanism with pH value 4.3 as a threshold, the culture solution lower than the value is subjected to re-acidification treatment, and the culture solution higher than the value is subjected to differential dilution and coating operation. Finally, Lactobacillus gasseri, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Bifidobacterium breve, Bifidobacterium lactis and Bifidobacterium longum are mixed at a preset ratio, and a sustained-release agent is added for storage. The method can significantly improve the screening efficiency of target probiotics, the stability of the composite preparation and the blood glucose regulation effect, and can be widely applied to the development of sugar-controlling probiotic products.

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.

This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.

This invention discloses a composition with bone-health-promoting functions and its applications, belonging to the field of microbial engineering. The composition comprises milk calcium, colostrum basic protein, and Bifidobacterium breve i1088 powder. The composition provided by this invention, which has a synergistic effect between milk calcium, colostrum basic protein, and Bifidobacterium breve i1088 powder, enhances the conversion rate of calcium from the blood to bone through the action of probiotics, thereby improving the actual utilization rate of calcium and effectively promoting bone health. Experimental data show that this composition significantly increases bone mineral density, bone volume fraction, and trabecular thickness in a female rat osteoporosis model, and significantly reduces trabecular spacing in the same model. The composition provided by this invention is suitable for promoting bone health and preventing and / or improving osteoporosis.

This invention discloses a novel application of Bifidobacterium breve CCFM1078 in relieving intestinal colic, belonging to the fields of microbial technology and pharmaceutical technology. The Bifidobacterium breve CCFM1078 provided by this invention can relieve intestinal colic in infants and young children, specifically in the following ways: (1) increasing the visceral pain threshold and reducing the frequency of defecation in rats to a certain extent; (2) reducing the number of chromaffin cells and 5-HT content in the colon of rats with intestinal colic; (3) reducing the serum TNF-α and IL-1β content in rats with intestinal colic; (4) reducing the hippocampal TNF-α and IL-6 content in rats with intestinal colic; and (5) increasing the propionic acid content in the cecal contents of rats with intestinal colic.

The application discloses Bifidobacterium breve and application of exopolysaccharide produced by the Bifidobacterium breve in prevention and treatment of hyperlipidemia acute pancreatitis, and belongs to the technical field of biological medicine. The application screens a Bifidobacterium breve with high yield of glucuronan exopolysaccharide, and the strain or the exopolysaccharide produced by the strain can help to reduce hyperlipidemia acute pancreatitis and reduce pancreatic lipid metabolism and inflammatory injury caused by HTG-AP.

The present application provides a Bifidobacterium breve. The strain has high yield of acetoin and has milk clotting function. The present application provides a fermenting agent comprising the Bifidobacterium breve. The preparation method of the fermenting agent is also provided. The present application also provides a fermented ovine colostrum, which contains a plurality of functional polypeptides. The present application also provides a preparation method of the fermented ovine colostrum. The method can simultaneously ensure high retention rate of nutrients in the ovine colostrum. The present application also provides a polypeptide. The polypeptide can inhibit angiotensin converting enzyme activity, improve vascular endothelial function or inhibit platelet aggregation, and has cardiovascular protection ability. The present application also provides a polypeptide composition. The present application also provides application of the Bifidobacterium breve, the polypeptide and / or the fermented ovine colostrum in the field of food or medicine for helping to enhance immunity.

This invention belongs to the field of biomedical technology, specifically relating to a composition for relieving respiratory discomfort, its applications, and products. The invention provides a composition for relieving respiratory discomfort, comprising a prebiotic and a compound probiotic composition; the prebiotic is fructooligosaccharide and polydextrose; the compound probiotic composition consists of *Bifidobacterium longum* subsp. *longum* BB536, *Bifidobacterium breve* M-16V, and *Bifidobacterium longum* subsp. *infant* M63. The composition provided by this invention can relieve airway inflammation, regulate the body's microecological balance, regulate immunity, significantly downregulate IgE, and has significant anti-inflammatory and anti-allergic effects. This composition can effectively treat infectious or allergic respiratory diseases, relieve cough, downregulate the content of pro-inflammatory factors, and reduce inflammation. This invention can effectively improve nasal allergy symptoms and reduce the frequency of nasal allergy recurrence. The composition of this invention has good application prospects in relieving respiratory discomfort.

The invention discloses a primer probe combination for detecting various bifidobacteria and application of the primer probe combination, and belongs to the field of molecular biological detection. The primer probe combination provided by the invention comprises a primer probe group for detecting bifidobacterium breve, a primer probe group for detecting bifidobacterium bifidum and a primer probe group for detecting bifidobacterium adolescentis. Based on the primer probe combination, the invention respectively develops a single PCR detection method and a triple PCR detection method for detecting the three bifidobacteria. Experimental results show that the detection method provided by the invention can be used for accurately detecting bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis. According to the invention, a foundation is laid for authenticity identification of products containing bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis, and a more convenient method is provided for detection of bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis.

The present disclosure relates to the field of biotechnology, and in particular to a preparation method for a high-activity freeze-dried Bifidobacterium preparation based on pH regulation, and an application. According to the present disclosure, by determining the influence of pH on the growth activity of the Bifidobacterium breve during culture and the influence on the survival rate of the freeze-dried bacterial cells, it is found that low pH can improve the resistance ability of the bacterial cells to freeze-drying and storage environment stress, which provides a basis for preparing the high-activity freeze-dried Bifidobacterium preparation.

A composition for treating insomnia, comprising a probiotic complex and traditional Chinese medicine components. The probiotic complex comprises Lactobacillus plantarum, Bifidobacterium lactis, Lactobacillus crispatus, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Lactobacillus reuteri, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus fermentum, Lactobacillus gasseri, Lactococcus lactis, Bifidobacterium longum, Lactobacillus salivarius, Bifidobacterium breve, Streptococcus thermophilus, Lactobacillus paracasei and Lactobacillus helveticus. The traditional Chinese medicine components are semen ziziphi spinosae, bulbus lilii, poria, semen nelumbinis and mori fructus. The composition may further comprise prebiotics selected from L-arabinose, β-glucan, inulin, erythritol, lactitol, vitamin C and γ-aminobutyric acid. The composition can be used for preparing pharmaceutical or food formulations, such as solid beverages, chewable tablets or oral lozenges. Clinical observation shows that the composition has the effect of relieving insomnia.

This invention discloses a process for preparing live Bifidobacterium bacteria that regulate immunity and its application. Using *Bifidobacterium animalis*, *Bifidobacterium breve*, and *Bifidobacterium longum* as production strains, a five-in-one preparation process is employed: solid-state fermentation of oat nutrient substrate with yeast; secondary anaerobic fermentation under starvation stress and assisted feeding resuscitation; low-temperature high-speed centrifugation for lossless concentration; emulsification with a compound stress-resistant protective agent; and gradient-temperature freeze-drying. The final product has a live bacteria count ≥ 2.0 × 10⁻⁶. 11 A highly active Bifidobacterium preparation with CFU / g, water activity ≤0.22, gastric acid resistance survival rate ≥85%, and accelerated survival rate of ≥85% after 3 months at 37℃ significantly enhances the colonization ability, immunomodulatory activity, intestinal tolerance, and long-term storage stability of Bifidobacterium.